文献速递肿瘤 PET/CT

18F-FDG PET/CT定量影像生物标志物对局部晚期非小细胞肺癌早期放化疗反应分类的可靠性

Reliability of Quantitative 18F-FDG PET/CT Imaging Biomarkers for Classifying Early Response to Chemoradiotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer.
PubMed 文献 · Clin Nucl Med · 2021-01-01

结果显示PET勾画观察者间变异性低,ΔSUVpeak是最稳健的反应预测因子,LASSO模型一致选择ΔSUVpeak和ΔMTV作为预测因子。

要点

  • ΔSUVpeak在不同观察者和重建算法间是最稳健的早期反应预测因子。
  • LASSO模型一致选择ΔSUVpeak和ΔMTV作为反应预测因子。
  • PET勾画观察者间变异性低,重建间观察者内变异性略高。

核心结论

  • FDG PET病灶勾画和影像生物标志物的变异性在不同观察者、扫描仪和重建算法间相对较低。
  • 客观的疗程中PET反应评估可能提高生物自适应放疗的精确性。

研究设计与样本

  • 患者在基线和外照射放疗第三周行18F-FDG PET/CT,使用GE Discovery STE或GE Discovery MI系统。
  • 所有PET扫描使用OSEM重建,GE-DMI扫描额外使用BSREM-TOF重建。
  • 原发肿瘤由3名观察者使用半自动梯度分割勾画。
  • LASSO逻辑回归模型在DSTE PET数据上训练,在DMI PET数据上独立测试。

主要发现

  • PET勾画的观察者间变异性在OSEM和BSREM-TOF重建下均较低,重建间观察者内变异性略高。
  • ΔSUVpeak在不同观察者和图像重建间是最稳健的反应预测因子。
  • LASSO模型一致选择ΔSUVpeak和ΔMTV作为反应预测因子。
  • 反应分类模型在DSTE队列上获得高交叉验证性能,在DMI队列上测试性能更多变。

关键数值与推荐

  • SUVmax、SUVmean、SUVpeak、MTV和总病变糖酵解与疗程中多学科临床反应评估进行相关性分析。
  • 评估指标包括勾画Dice相似性和反应分类曲线下面积。

临床怎么用

  • 疗程中18F-FDG PET/CT定量评估可用于局部晚期非小细胞肺癌早期放化疗反应分类,支持生物自适应放疗。
  • ΔSUVpeak和ΔMTV可作为跨观察者和重建算法相对稳健的反应预测指标。

局限性

  • 反应分类模型在DMI队列上的测试性能较多变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE OF THE REPORT: We evaluated the reliability of 18F-FDG PET imaging biomarkers to classify early response status across observers, scanners, and reconstruction algorithms in support of biologically adaptive radiation therapy for locally advanced non-small cell lung cancer. PATIENTS AND METHODS: Thirty-one patients with unresectable locally advanced non-small cell lung cancer were prospectively enrolled on a phase 2 trial (NCT02773238) and underwent 18F-FDG PET on GE Discovery STE (DSTE) or GE Discovery MI (DMI) PET/CT systems at baseline and during the third week external beam radiation therapy regimens. All PET scans were reconstructed using OSEM; GE-DMI scans were also reconstructed with BSREM-TOF (block sequential regularized expectation maximization reconstruction algorithm incorporating time of flight). Primary tumors were contoured by 3 observers using semiautomatic gradient-based segmentation. SUVmax, SUVmean, SUVpeak, MTV (metabolic tumor volume), and total lesion glycolysis were correlated with midtherapy multidisciplinary clinical response assessment. Dice similarity of contours and response classification areas under the curve were evaluated across observers, scanners, and reconstruction algorithms. LASSO logistic regression models were trained on DSTE PET patient data and independently tested on DMI PET patient data. RESULTS: Interobserver variability of PET contours was low for both OSEM and BSREM-TOF reconstructions; intraobserver variability between reconstructions was slightly higher. ΔSUVpeak was the most robust response predictor across observers and image reconstructions. LASSO models consistently selected ΔSUVpeak and ΔMTV as response predictors. Response classification models achieved high cross-validated performance on the DSTE cohort and more variable testing performance on the DMI cohort. CONCLUSIONS: The variability FDG PET lesion contours and imaging biomarkers was relatively low across observers, scanners, and reconstructions. Objective midtreatment PET response assessment may lead to improved precision of biologically adaptive radiation therapy.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Horn KP, Thomas HMT, Vesselle HJ, et al. Reliability of Quantitative 18F-FDG PET/CT Imaging Biomarkers for Classifying Early Response to Chemoradiotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer. Clin Nucl Med. 2021. PMID: 34172602. doi:10.1097/RLU.0000000000003774

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。